As of 2025-05-17, the Relative Valuation of Ultragenyx Pharmaceutical Inc (RARE) is (157.73) USD. This relative valuation is based on P/E multiples. With the latest stock price at 35.61 USD, the upside of Ultragenyx Pharmaceutical Inc based on Relative Valuation is -542.9%.
The range of the Relative Valuation is (137.19) - (225.57) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.5x - 38.5x | 24.7x |
| Forward P/E multiples | 23.4x - 45.6x | 29.2x |
| Fair Price | (137.19) - (225.57) | (157.73) |
| Upside | -485.3% - -733.4% | -542.9% |
| Date | P/E |
| 2025-05-15 | -5.95 |
| 2025-05-14 | -5.93 |
| 2025-05-13 | -6.05 |
| 2025-05-12 | -6.17 |
| 2025-05-09 | -6.00 |
| 2025-05-08 | -6.15 |
| 2025-05-07 | -5.71 |
| 2025-05-06 | -5.99 |
| 2025-05-05 | -6.64 |
| 2025-05-02 | -6.71 |
| 2025-05-01 | -6.66 |
| 2025-04-30 | -6.66 |
| 2025-04-29 | -6.50 |
| 2025-04-28 | -6.49 |
| 2025-04-25 | -6.51 |
| 2025-04-24 | -6.43 |
| 2025-04-23 | -6.37 |
| 2025-04-22 | -6.14 |
| 2025-04-21 | -6.05 |
| 2025-04-17 | -6.10 |
| 2025-04-16 | -5.98 |
| 2025-04-15 | -6.04 |
| 2025-04-14 | -5.97 |
| 2025-04-11 | -5.83 |
| 2025-04-10 | -5.67 |
| 2025-04-09 | -5.79 |
| 2025-04-08 | -5.31 |
| 2025-04-07 | -5.49 |
| 2025-04-04 | -5.54 |
| 2025-04-03 | -6.00 |
| 2025-04-02 | -6.04 |
| 2025-04-01 | -5.78 |
| 2025-03-31 | -6.19 |
| 2025-03-28 | -6.46 |
| 2025-03-27 | -6.64 |
| 2025-03-26 | -6.49 |
| 2025-03-25 | -6.61 |
| 2025-03-24 | -6.72 |
| 2025-03-21 | -6.69 |
| 2025-03-20 | -6.64 |
| 2025-03-19 | -6.78 |
| 2025-03-18 | -6.64 |
| 2025-03-17 | -6.77 |
| 2025-03-14 | -6.72 |
| 2025-03-13 | -6.71 |
| 2025-03-12 | -6.88 |
| 2025-03-11 | -6.55 |
| 2025-03-10 | -6.41 |
| 2025-03-07 | -6.60 |
| 2025-03-06 | -6.84 |